Roche Holding AG (RO, ROG,RHHBY) on Wednesday announced that it has received CE mark for its Elecsys Dengue Ag test - a high-throughput, fully automated immunoassay to be used as an aid in the diagnosis of an acute dengue virus infection.
The Elecsys Dengue Ag is an in-vitro diagnostic immunoassay for the qualitative detection of the NS1 antigen of the dengue virus in human serum and plasma, a key marker of acute infection during the first days of illness.
It is intended for use on Roche's fully automated cobas e immunoassay analysers: cobas e 801 systems and cobas e 402 platforms - a widely used platform with an extensive installed base in laboratories worldwide.
The test has been shown to reliably detect NS1 antigen for all four dengue virus serotypes - DENV-1, DENV-2, DENV-3, and DENV-4.
In clinical studies, it demonstrated 94.90 percent sensitivity in PCR-confirmed positive samples and 99.96 percent relative specificity in a large cohort of healthy blood donors.
The Elecsys Dengue Ag test is expected to provide reliable and fast results, enhanced efficiency and traceability as well as a comprehensive response across the entire patient journey.
For comments and feedback contact: editorial@rttnews.com
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.